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Abstract
The coffee fruit is a high source of bioactive compounds such as phenolic acids and methylxanthines, comprising
chlorogenic acids and caffeine, respectively. Extract from this matrix may be used as supplement or active ingredient of
functional foods, energy drinks, cosmetics or drugs. Safety of caffeine- and chlorogenic acid-rich encapsulated and nonencapsulated hydroethanolic extracts from green coffee fruit (GCFE) was assessed by acute and subacute toxicity tests. In
the acute test, oral single dosage until 1000 mg/kg per body weight (bw) did not show any adverse effect on both female
and male mice according to the Hippocratic screening and clinical parameters for a period of 14 days. While the oral
median lethal dose of non-encapsulated GCFE was 5000 mg/kg bw/day, that of encapsulated GCFE was not detectable
likely due to the delayed release of caffeine and other compounds from GCFE. Non-encapsulated GCFE displayed a
stimulating effect at a dose of 1000 mg/kg bw/day after 30 min of oral administration, but not after 60 min. Daily
consumption of encapsulated GCFE for 30 days showed no adverse effect in male rats even at the highest dose.
Extrapolating this value of no-observed-adverse-effect level (1000 mg/kg bw/day) to human consumption, a human
equivalent dose of 189 mg/kg bw/day or 11.34 g/day could be estimated for encapsulated GCFE considering a 60 kg adult
body weight.
Keywords: Mice, No-observed-adverse-effect level, Rats, Safety, 5-O-Caffeoylquinic acid

1. Introduction

N

ot only the efﬁcacy but also the safety of any
medicine, food component or additive, dietary supplement, chemical, or substance is of
paramount importance. So, before using a

substance in humans, including encapsulated
products, its safety must be assessed by in vitro
tests, in silico studies and studies in animals,
especially rodents and other species [1,2]. A lot of
information is in fact required by the regulatory
agencies for a petition for use of a new food
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ingredient, among which are the estimated daily
intake (EDI), acceptable daily intake (ADI), noobserved-adverse-effect level (NOAEL), etc. [3].
Microencapsulation is a technique applied to
protect bioactive from external environment, to
prevent the interaction between core and food matrix nutrients, and/or to provide a controlled release
of compounds from core [4,5]. The development of
nano/microencapsulation systems that can carry,
protect and deliver food ingredients has been a key
breakthrough in the food industry [6]. However, the
development of oral controlled release systems is
still a challenge, due to the inability to restrain and
localize the system at targeted areas of gastrointestinal tract [4].
Several researches have been developed aiming to
improve safety of substances using different
microencapsulation techniques [7e9]. With speciﬁc
reference to systems for bioactive compounds
release, safety issues concern also the features of
carrier materials [10,11]. Because of their excellent
biocompatibility, non-toxicity, biodegradability and
ability to provide controlled-drug release, natural
polymers such as maltodextrin (MD) and gum
Arabic (GA) are often used to prepare microspheres
[11]. For this purpose, the Joint Expert Committee
on Food Additives (JECFA) of the Food and Agriculture Organization (FAO) and the World Health
Organization (WHO) provided online documents
about the acceptable daily intake of substances
applied in encapsulation technologies, based on
animal toxicology or human studies and expressed
in mg per kg of body weight per day (mg/kg bw/
day). Whereas, the ADI values of GA and MD are
not speciﬁed, likely because these substances are
considered to display very low or no toxicity, limited
daily intakes are reported for other polymers such
as polypropylene glycol alginate (ADI ¼ 70 mg/
kg bw/day) and beta cyclodextrin (ADI ¼ 5 mg/
kg bw/day) [1,12].
Due to their safety and cost-effectiveness, GA and
MD (DE < 20) were chosen in this study as wall
material to encapsulate hydroethanolic extracts
from the whole fruit of Coffea canephora. The
resulting dry extracts, which are rich in caffeine and
chlorogenic acids, are claimed to be used as food
additive and/or nutritional supplement in foodstuff.
The health beneﬁts of green coffee extract are
already well documented [13e15]; among them,
antidiabetic [16], antiobesogenic [13,17], antioxidant
[18] and antihypertensive [19] effects stood out in
clinical studies, but safety of isolated compounds
such as chlorogenic acid [20,21] and, especially,
caffeine is still a matter of debate [22e24].

Heimbach et al. [25] assessing the safety of ethanolic extracts from whole cherry coffee fruit through
daily ingestion for 90 days by rats (approximately
3446 and 4087 mg/kg bw/day) did not observe any
adverse effects. However, this type of extract (Coffeeberry® Energy Brand) was used in non-encapsulated form and had remarkably lower average
contents of chlorogenic acids (0.3e14%) and caffeine
(0.0e4.46%) [26] than that used in the present study.
The main objective of this study was to test the
safety of encapsulated and non-encapsulated extracts from the whole green coffee fruit (GCFE).
With this aim in mind, we determined the acute
safety, acute effect on behavior and locomotor activity, and the oral median lethal dose of GCFEs in
mice. In addition, since preclinical studies are a vital
preliminary step to assess safety before human
consumption, the NOAEL of encapsulated GCFE
was also assessed by subacute 30-day study in rats.

2. Materials and methods
2.1. Plant material
Powder extracts tested by acute and subacute
toxicity methods were obtained from the green
fruits (GCFE) of an organic culture of C. canephora
grown in the Experimental Farm of Leopoldina
(Minas Gerais, Brazil) belonging to the Company
EPAMIG.
2.2. Extraction and microencapsulation process
Powders were submitted to percolation extraction
(PE) at a ﬂow rate of 1.0 mL/min. A mass of 900 g
batch of dried whole coffee fruit powder (particle
size between 250 and 710 mm) was uniformly
moistened with thrice its weight (2.7 kg) of a 68% (w/
w) ethanol solution in water for 12 h (pre-swelling
phase). After carefully transferring and evenly
loading this material into a 10-L stainless steel
percolator (Revitec Ltda, S~
ao Paulo, SP, Brazil),
more solvent was added to achieve a solid-to-solvent ratio of 0.9:10 (w/w) and allowed to remain in
contact with the powder for more 24 h (intermediate
maceration phase). The ﬂow rate was then adjusted
to 0.20 ± 0.05 mL/min at room temperature
(25±1  C) (percolation phase). The residual solvent
was removed at 40±2  C under vacuum in a rotary
evaporator, model R-220 SE (Buchi, Flawil,
Switzerland), taking care to maintain 15% of solids
in the extract before spray drying.
For microencapsulation, a carrier dispersion containing 30% of solids comprised of maltodextrin

(MD) and gum Arabic (GA) (1:1, w/w) was added to
the concentrated extract (1:1, w/w). The resulting
dispersions were placed overnight in refrigerator
(5±1  C) to complete the hydration according to
Faria et al. [27] and then dried with a laboratory
scale spray dryer under the following conditions:
feed ﬂow rate 500 mL.h1, drying air ﬂow rate 45,000
OU 45000 mL.min1, inlet temperature 160 ± 2  C
and outlet temperature 125 ± 2  C.
2.3. Physicochemical characterization of extracts
Free and microencapsulated spray dried extracts
were analyzed by HPLC-DAD according to Rodrigues and Bragagnolo [28], whereby 5 mg of each
extract were suspended in 1250 mL of a methanol:
water (80:20 v/v) solution, and mixtures vortexed for
30 s and centrifuged at 25,000 g for 10 min at 10  C.
Supernatants were ﬁltered through membranes
with 0.45 mm pore diameter (Millipore, S~
ao Paulo,
SP, Brazil) and injected into the HPLC-DAD, model
10 (Shimadzu, Kyoto, Japan).
The quantitative analysis was carried out with a
HPLC equipped with a LC10 binary pump (Shimadzu), degasser with helium (DGU-2A), automatic
injection system (SIL-10A) and a SPD-M-10A diode
array detector (DAD-UV-Vis) (Shimadzu). Bioactive
compounds were separated out using a Shim-pack
ODS-C18 column (5 mm, 250  4.6 mm, Shimadzu,
Kyoto, Japan) coupled to an ODS-C18 pre-column
(5 mm, 4  3 mm, Phenomenex, Torrance, CA, USA).
Separation was carried out according to a gradient
elution mode with a mobile phase made up of solvent A consisting of 80% (v/v) 10 mM citric acid (pH
2.5) and 20% (v/v) methanol and solvent B consisting of methanol [28]. The ﬂow rate was 1.0 mL/min
and the column oven temperature 30  C. To detect
5-caffeoylquinic acid (5-CQA), trigonelline and
caffeine, chromatograms were processed at wavelengths of 262, 272 and 325 nm, respectively, and
external calibration curves of the same compounds
at six concentration levels were used for
quantiﬁcation.
The moisture content was measured gravimetrically in a circulation oven at 105  C. The water activity (Aw) of samples was measured with a Testo
650 thermo-hygrometer (Testo AG, Lenzkirch,
Germany) and a hermetic chamber, while the particle size by a laser diffractometer, model Mastersizer X (Malvern Instruments, Malvern, UK), ﬁtted
with 45-mm lens. Particles were dispersed in 99.9%
ethanol.
The ability of encapsulated (En-GCFE) and nonencapsulated (Non-En-GCFE) extracts to scavenge
DPPH (2-2-diphenyl-1-pycryhidrazyl) radical was
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investigated according to the method reported previously by Brand-Williams et al. [29] with slight
modiﬁcation. Brieﬂy, 5.0 mg of Non-En-GCFE or
15 mg of En-GCFE were dispersed in 2.0 mL of a
(50:42:8 v/v/v) methanol: water: acetic acid solution
agitated for 1 min with a vortex mixer. Afterward,
the sample was kept in an ultrasonic bath, model
USC 800 (Unique, S~
ao Paulo, SP, Brazil), for 10 min,
centrifuged at 15,000 g for 15 min at 20  C and then
ﬁltered through a nylon ﬁlter (45 mm). The resulting
GCFE solution was diluted ﬁve folds to determine
the concentration required to obtain a 50% antioxidant effect (EC50), and then 0.1 mL of each dilution
were added to 3.9 mL of a 6  105 mol/L DPPH
solution. The mixture was then mixed and left for
30 min at room temperature in the dark. The
absorbance of samples was measured at 515 nm
using a UV-VIS Spectrophotometer, model UV-1800
(Shimadzu, Chiyoda-ku, Tokyo, Japan). The analysis
was done in triplicate either for standards or extracts. The antioxidant capacity of each extract was
determined as percentage absorbance reduction.
Physicochemical characteristics of powders are listed in Table 1.
2.4. Toxicity study methods
For toxicity study, dosage of En-GCFE and NonEn-GCFE was equated by using 5-CQA as the
chemical marker. Since its mass in Non-En-GCFE
was about 3.5 folds that in En-GCFE, a 3.5 correction
factor was applied for adjustment of the test dosage.
Acute oral toxicity and subacute oral toxicity
studies were carried out in strict accordance with
the recommendations in the Test Guidelines 423
and 407 of the Organization for Economic Cooperation and Development (OECD) [30,31]
respectively. The assays were conducted at Federal
University of Mato Grosso (UFMT) Biochemistry
Laboratory belonging to the Department of Chemistry (Cuiab
a, MT, Brazil), and the protocols were
approved by the Committee on the Ethics of Animal
Experiments of the UFMT under number
23108101038/2015-91. Experimental procedures
were conducted in compliance with the Brazilian
College of Animal Experimentation (COBEA) and
with the principles set forth in the Principles of
Good Laboratory Practice and Compliance Monitoring [32].
2.4.1. Animals
Female and male SwisseWebster albino mice Mus
musculus (20e25 g) and male albino rats Rattus norvegicus (180e220 g) were used. Animals, provided by
the Central Animal House of the UFMT, were
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acclimated for 6 days in polypropylene cages before
treatments. Throughout the trials, animals were
kept in the Animal Care Unity of the Biochemistry
Laboratory
under
controlled
temperature
(20 ± 1  C), relative humidity (50 ± 5%), 12 h light/
dark cycle, and provided with water and feed
(Nuvilab® autoclavable CR1 Sogorb, S~
ao Paulo,
Brazil) ad libitum except when they were fasted
overnight prior to blood sampling or during
behavioral testing.
2.4.2. Acute toxicity tests
Acute oral assays of En- and Non-En-GCFEs were
performed on male (n ¼ 36) and female (n ¼ 36)
mice in order to determine the oral median lethal
doses (LD50), i.e., the dose which kills 50% of a
group of test animals, as well as the tolerable dosages to conduct the subacute toxicity tests in rats.
Groups of 6 mice/sex/dose received single dose of
100, 500, 1000, 2500, 5000 mg/kg of body weight (bw)
or vehicle (distilled water, 1 mL/kg bw) by orogastric gavage, after a 12 h-overnight fast. Animals were
monitored individually for clinical signs of toxicity
or mortality by using the Hippocratic screen according to Malone and Robichaud [33] in the open 5,
10, 15, 30, 60, 120, and 240 min following administration of powders, and daily for a period of 14 days.
Body weight, food and water intake were measured
daily. On the 15th day, animals were euthanized by
carbon dioxide overdose and subjected to gross
necropsy (i.e., examination of external surface of the
body, all oriﬁces, and the thoracic and abdominal
cavities and their contents). Organs were removed
to determine the relative weight, which was
expressed as percentage of organ weight to body
weight.
Table 1. Physicochemical characteristics of the encapsulated and nonencapsulated green coffee fruit extracts (GCFEs).

Appearance
Moisture content (%)
Water activity
Particle size distribution (mm)
Total chlorogenic acids (%)a
Caffeine (%)
Trigonelline (%)
Antioxidant capacity (%)b

Encapsulated
GCFE

Non-encapsulated
GCFE

Pale yellow
powder
1.65 ± 0.06
0.10 ± 0.08
1.19e12.65
6.08 ± 0.07
3.08 ± 0.01
1.02 ± 0.08
9.30 ± 0.8

Greenish/brown
powder
2.04 ± 0.06
0.70 ± 0.01
0.88e4.60
21.70 ± 0.40
8.75 ± 0.20
3.55 ± 0.12
2.23 ± 0.08

a
3-O-caffeoylquinic acid, 4-O-caffeoylquinic and 5-O-caffeoylquinic acid.
b
Expressed as IC50 of DPPH scavenging activity (mg.mL1). The
extraction solvent used in the extraction process was ethanol:water (68%, w/w) for both encapsulated and non-encapsulated
GCFE. All values are given as means of triplicates ± standard
deviations.

2.4.3. Subacute toxicity tests
Male Wistar rats (n ¼ 40) were placed in individual metabolic cages and randomly distributed
into one of the following groups (n ¼ 10/group):
control group (C), rats treated with 100 mg/kg bw/
day of En-GCFE (En-GCFE100), rats treated with
500 mg/kg bw/day of En-GCFE (En-GCFE500), and
rats treated with 1000 mg/kg bw/day of En-GCFE
(En-GCFE1000). The control group received the
vehicle (distilled water, 1 mL/100 g bw/day), and the
En-GCFE dose was adjusted from the Non-EnGCFE one using the 3.5 correction factor. To
dissolve microparticles in the vehicle, the powder
was weighed daily into a conical tube and solubilized in distilled water using a vortex mixer up to the
achievement of 1 mL solution/100 g bw.
Treatment was administered orally once a day for
30 days. Body weight of animals, food intake and
feces mass were determined once a week, while
water consumption every 3 days. Rats were also
observed every two days for behavior alteration or
for presence of any signs and symptom of toxicity.
Near the end of the study, they were evaluated by
functional observational battery (FOB) that assessed
excitability, autonomic function, gait, sensorimotor
coordination, reactivity, sensitivity, and other
abnormal clinical signs in an open ﬁeld. At the end
of the study, after fasting for 12 h, animals were
euthanized. Blood samples collected in ethylenediaminetetraacetic acid (EDTA) in Vacutainer®
tubes were used to determine complete blood count
(CBC) using a veterinary hematology analyzer,
model Poch-100iV Diff (Sysmex do Brazil Indústria e
Com
ercio, S~
ao Jos
e dos Pinhais, PR, Brazil). Other
blood samples collected in anticoagulant-free
Vacutainer® tubes were analyzed for biochemical
parameters [glucose (GLU), urea (Ur), uric acid
(UA), creatinine (Cre), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gglutamyl transferase (GGT), amylase, total bilirubin
(TBILI), direct bilirubin (DBILI), indirect bilirubin
(IBILI), total cholesterol (CHO), HDL cholesterol,
LDL cholesterol, triglycerides, alkaline phosphatase
(ALP), total protein (TP), albumin and globulin] in
an automatic biochemical analyzer, model Labmax
Plenno (Labtest, Belo Horizonte, MG, Brazil), and
for hormonal cortisol as stress biomarker by chemiluminescence using a immunoassay system, model
Immulite® 1000 (Siemens Healthineers, Belo Horizonte, Brazil).
Liver, kidney, stomach, spleen, heart, lungs, and
brain were removed and their relative weights,
expressed as percentages of organ weight to body
weight, were determined before placing fragments
in 10% formalin for histological analysis.

2.4.4. Histopathological study
Histological sections of liver, brain, testicles,
stomach, lungs, spleen, heart, kidneys, and small
and large intestine were processed by a conventional histopathological method, followed by
staining with hematoxylin and eosin and visualization by optical microscopy with a 40X objective.
Animal tissues were examined blindly, and the
criteria for assessing the occurrence of lesions in
organs were done according to the methodology
proposed by Giordani et al. [34]. Brieﬂy, the criteria
for liver injury were vacuolization of hepatocytes
and pyknotic hepatocyte nuclei, number of Kupffer
cells and enlargement of sinusoids. Moreover, the
histopathological change of lungs was based on
congestion, edema, inﬂammation and hemorrhage.
Microscopic features of the organs of En-GCFE-fed
rats were compared with those of the control
group.
2.4.5. Estimation of human dose
The human equivalent dose (HED) was estimated,
from the no-observed-adverse-effect level (NOAEL)
of En-GCFE determined in male rats by subacute
toxicity tests, by means of the empirical equation
[35]:
HED (mg/kg) ¼ NOAEL (mg/kg bw/day) x Km
ratio
(1)
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animals; at the end of the test, they were euthanized
by carbon dioxide overdose.
The apparatus consisted of a wooden box
(40  60  50 cm) with visible lines dividing the ﬂoor
into twelve equal squares drawn using a black
sticker. The number of squares crossed with all
paws (crossings) or rearing was counted in a 6-min
session. The light was maintained at minimum and
any interference such as noise was avoided during
the test. Mice were individually placed in the center
of the apparatus and allowed to explore freely, while
a blinded observer scored the number of times a
mouse crossed one of the grid lines with all four
paws or rearing occurrence (event).
2.6. Data analysis
The GraphPad Prism (GraphPad Software 5.00,
San Diego, CA, USA) was used for statistical analysis and plotting. The results of parametric tests
were expressed as mean ± standard error of the
mean (SEM) or standard deviation, according to
circumstances. To compare the means of more than
two samples from different treatments we used oneway analysis of variance (ANOVA), observing the
signiﬁcance by F-test and, when signiﬁcant,
TukeyeKramer test at 5% and 1% probability levels.

3. Results and discussion
3.1. Acute toxicity

where the NOAEL corresponds to the effective animal dose, and the Km ratio to the ratio of human Km
factor to that of the animal. The Km factors were
estimated by dividing the average body weight (kg)
of human or rats by its body surface area (m2). The
average human body weight and body surface area
were considered to be 60 kg and 1.62 m2, respectively, while the average animal body weight was
that determined at the end of the toxicological study
(around 0.3 kg) and the body surface 0.043 m2 [35].
2.5. Behavioral test
Male mice (n ¼ 60) were also treated with NonEn-GCFE and analyzed for locomotor activity by the
open-ﬁeld test as described by Zomkowski et al.
[36]. The experimental conditions included four
doses of Non-En-GCFE (100, 500, 1000 or 2000 mg/
kg bw, n ¼ 6 per group), and a control group fed
with vehicle (distilled water 1 mL/kg bw, n ¼ 6 per
group). Animals were pretreated with extract or
vehicle twice, after 30 min and 1 h prior to the openﬁeld test. The duration of this study was around 10
(ten) days with around six days of acclimatization of

3.1.1. Hippocratic screening
The Hippocratic screening is often used to provide
a general estimate of pharmacological and toxicological nature of a given compound [37]. For animal
welfare reasons, starting doses of Non-En-GCFE
and En-GCFE used in this study ranged from 100 to
1000 mg/kg of body weight (bw). No behavioral alterations or death were observed in both female and
male mice submitted to these dosages. A mild
analgesic effect was noticed at doses from 500 to
1000 mg/kg bw both in Non-En-GCFE and EnGCFE treatment groups, but this effect was reversed
around 4 h after a single dose administration both in
male and female mice.
In accordance with OECD guideline 423 [30], which
recommends performing a limit test when available
information suggests that mortality is unlikely at the
highest starting dose level, dosages of 2500 and
5000 mg/kg bw were also assessed in a second step.
Although the additional upper dose level is usually
tested for substances with relatively low acute
toxicity hazard, under certain circumstances it may
pose a danger to the vulnerable population [31].

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2020;28:337e355

342

JOURNAL OF FOOD AND DRUG ANALYSIS 2020;28:337e355

ORIGINAL ARTICLE

Non-En-GCFE at a dosage of 5000 mg/kg bw
caused tonic convulsion followed by death of four
male mice and three female mice. Two male mice
died right after the administration of the maximum
dose, and two more did so after a period of ataxia of
about 4 h. Among females, two showed an acute
tonic convulsion episode and subsequent death,
while the third remained ataxic for about 8 h and
then died. No human endpoints criteria were
adopted to minimize the suffering before the death
of these animals because the deaths were very fast
in half part of the animals, and between animals that
showed symptoms of ataxia before die, the survival
was expected. On the other hand, to determine the
median lethal dose (LD50) in toxicity studies, no
euthanasia intervention should be performed before
the end of the assay in order not to alter the
doseeresponse results.
Even though doses of 2500 mg/kg bw of Non-EnGCFE and 5000 mg/kg bw of En-GCFE did not
cause any death, other effects on the autonomic
system were noticed among both female and male
mice such as the Straub tail phenomenon accompanied by piloerection after about 30 min as well as
initial excitation with increased motor activity and
respiratory rate in the ﬁrst 15 min. Then, an
increased fugue reaction and aggressiveness were
observed especially at 2500 mg/kg bw of Non-EnGCFE in mice of both sexes. These side effects are
characteristic of caffeine intoxication present with
hyperventilation, dizziness, anxiety, tinnitus,
tremor, and agitation [38].
Enophthalmos after 60 min along with palpebral
ptosis (more sedation than a true blepharospasm)
were observed among great part of the animals that
survived the treatment with 5000 mg/kg bw of EnGCFE and with 2500e5000 mg/kg bw of Non-EnGCFE. These effects were reversed after 8 h of
administration, and no other deaths occurred after
this period among the other treatment groups for
14-day observation.
3.1.2. Median lethal dose (LD50)
In accordance with the criteria established by the
OECD guideline 423 [30], Non-En-GCFE belongs to
the hazard category 5, since the oral LD50 for both
male and female mice was achieved at the dose of
5000 mg/kg bw. In this category includes substances
characterized by relatively low acute toxicity hazard,
with oral or dermal LD50 in the range of
2000e5000 mg/kg or equivalent doses by other
routes.
As reported by Schafer et al. [39] oral LD50 of
chlorogenic and caffeic acids in red wing blackbird

>100 mg/kg bw, corresponding to 0.282 and
0.555 mmol/kg, respectively, but sex and strain of
model animals were not provided. Despite the lack
of information in the scientiﬁc literature about LD50
values of these substances administered orally to
rats in studies performed under good laboratory
practice or equivalent, a Non-Commercial Scientiﬁc
and Production Partnership reported acute oral
toxicity of chlorogenic acid >2000 mg/kg bw in rats
and >1580 mg/kg bw in mice (NSPP, 2006). In a
systematic review, Adamson [2] reported 367 mg/kg
bw as the most accurate acute median lethal dose of
caffeine administered orally in male albino rats.
Based on these ﬁndings, the caffeine content in
Non-En-GCFE may have been responsible for the
death of more than 50% of mice given that the
5000 mg/kg bw dose provided around 400 mg/kg bw
of caffeine. The fatal blood concentration of caffeine
in humans is 80e100 mg/L, which means that, in
order to achieve this concentration, a person would
need to ingest as much as 5000e10,000 mg of pure
caffeine [40]. In addition, it has been speculated that
caffeine's mechanism of death is usually associated
with ventricular arrhythmia provoked by a block of
the adenosine receptor, due to similarity of its molecular structure to that of adenosine. The increased
intracellular
calcium
concentration,
causing
noradrenaline release and sensitizing dopamine
receptors, can trigger arrhythmia [41]. Although the
dosages of En-GCFE and Non-En-GCFE were
equivalent, it was not possible to determine the oral
LD50 of the former, probably due to the delayed
release of caffeine and other compounds from
GCFE.
3.1.3. Body weight, food intake and water
consumption
As shown in Table 2, in the male group treated
with 2500 mg/kg bw of En-GCFE the mean weekly
body weight gains were signiﬁcantly lower than
those in the controls after 7 and 14 days (p < 0.05).
However, this effect was not dose-dependent since
no difference was observed with the highest dosage
in the control group. On the other hand, the female
body weight values were always close to those of the
control group.
The food intake (Fig. 1) and food efﬁciency (data
not shown) were also similar among females in both
treatments. On the other hand, among males, the
food efﬁciency at dosage of 2500 mg/kg of Non-EnGCFE was 31% lower compared to En-GCFE.
Nonetheless, among males treated with Non-EnGCFE, the food intake and food efﬁciency were
similar to the control group. It is well known that

food efﬁciency, which is the ratio of body weight
gained per gram of food eaten, is subject to sexspeciﬁc responses to the effects of voluntarily
increased food intake by animals. In general, female
animals exhibit a higher percent increment of body
fat than males [42], which corroborates with the
higher food efﬁciency observed in this study for
females compared to males at all dosages.
As far as water consumption is concerned, despite
the variations in both sex and treatment, groups did
not show any signiﬁcant difference among them
(Fig. 2). Based on these results, we can conclude that
single doses of En-GCFE and Non-En-GCFE did not
interfere with food intake or water consumption.
3.1.4. Relative organ weight
Changes in body and organ weights are a clear
indication of damage caused by the ingestion of a
toxic substance, the latter being considered as the
most sensitive indicator of its toxic effect [43]. As it
can be seen in Table 3, no signiﬁcant differences in
relative organ weight were observed between

female groups treated with Non-En- and En-GCFE
(p > 0.05), with the exception of the liver one at
dosage of 1000 mg/kg bw of the latter extract that
showed higher value compared to the other
groups. However, this effect was not dosagedependent since the groups treated with 2500 and
5000 mg/kg bw did not show any signiﬁcant difference between them. Relative liver weight, which
is considered a more sensitive toxicity indicator
than absolute liver weight [44], can be enlarged by
several conditions that may be basically divided
into two categories: those without histopathological alterations and injuries caused by diseases
such as tumors [45,46]. Conditions of the former
category, which can be brought about by a variety
of compounds metabolized by the liver such as
drugs, food additives, insecticides, carcinogens and
normal body constituents such as cortisone,
thyroxine, estradiol, testosterone and androsterone
[46], were likely to occur in the present study as a
result of oral acute toxicity tests, since liver necropsy compared to the control group did not show

Table 2. Results of the oral acute toxicity study using female and male mice.
Group

Dose (mg/kg bw)

Sex

Body weight (g)a
Day 0

Day 7

Clinical Signs

Macroscopical
lesions findings

Mortality (%)
(Dead/total)

Day 14

b

Non-En-GCFE
G1
0
G2

100

G3

500

G4

1000

G5

2500

G6

5000

M
F
M
F
M
F
M
F
M
F
M
F

23.1
25.4
22.1
22.7
22.4
24.6
22.1
24.2
22.7
24.3
22.6
26.0

±
±
±
±
±
±
±
±
±
±
±
±

0.7
0.8
0.9
1.2
0.6
0.9
0.8
0.8
0.6
0.6
0.8
0.5

32.0
29.8
23.0
26.7
31.0
29.0
27.9
27.3
33.3
26.2
27.7
28.8

±
±
±
±
±
±
±
±
±
±
±
±

1.1
0.7
0.8
1.0
0.4
0.8
1.5
1.0
1.1
1.0
1.3
0.7

35.1
30.6
37.5
28.5
34.8
30.2
32.4
29.2
37.0
28.5
32.4
29.7

±
±
±
±
±
±
±
±
±
±
±
±

0.6
0.9
0.8
1.2
0.8
0.9
1.5
0.7
1.3
0.7
1.7
0.6

N
N
N
N
N
N
N
N
Ab
Ab
Ab
Ab

0
0
0
0
0
0
0
0
0
0
0
0

0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
0% (0/6)
66.6% (4/6)
50% (3/6)

M
F
M
F
M
F
M
F
M
F
M
F

23.2
23.2
24.5
22.0
22.8
23.7
22.9
23.1
23.7
24.9
22.4
24.2

±
±
±
±
±
±
±
±
±
±
±
±

0.5
0.6
0.7
0.5
0.9
0.7
0.5
0.7
0.3
0.4
0.6
0.6

30.7
28.0
33.2
28.0
30.7
28.5
28.8
26.9
24.6
26.1
27.0
27.6

±
±
±
±
±
±
±
±
±
±
±
±

1.1
0.9
0.2
0.5
1.1
0.8
0.7
0.9
0.3**
0.6
1.2
0.3

34.2
30.0
34.0
31.1
34.8
30.6
34.1
30.2
30.7
28.4
32.0
29.3

±
±
±
±
±
±
±
±
±
±
±
±

1.0
0.8
0.3
0.4
0.9
0.6
1.1
1.2
0.3**
0.5
0.8
0.3

N
N
N
N
N
N
N
N
N
N
Ab
Ab

0
0
0
0
0
0
0
0
0
0
0
0

0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

c

En-GCFE
G1
0
G2

100

G3

500

G4

1000

G5

2500

G6

5000

(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)
(0/6)

*p  0.05 and **p  0.01 represent signiﬁcant differences from the control male or female group. G1 ¼ Control; G2 ¼ Group 2 (100 mg/
kg bw); G3 ¼ Group 3 (500 mg/kg bw); G4 ¼ Group 4 (1000 mg/kg bw); G5 ¼ Group 5 (2500 mg/kg bw); G6 ¼ Group 6 (5000 mg/kg bw);
M ¼ male; F ¼ female; N ¼ Normal; Ab ¼ Abnormal.
a
Results were expressed as mean ± standard error of mean (SEM) of 6 rats.
b
Encapsulated (En-) and.
c
Non-encapsulated (Non-Enc-) green coffee fruit extract (GCFE). Analysis by ANOVA followed by TukeyeKramer test.
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Fig. 1. Female and male mice food intake during 14-day after single dose of En-GCFE and Non-En-GCFE. *encapsulated (En-) and nonencapsulated (Non-En-) green coffee fruit extract (GCFE).

any macroscopic alteration, both in females and
males.
In male groups, statistically signiﬁcant decreases
(p < 0.05) were observed for relative kidney weight
at dosages of 500 and 5000 mg/kg bw of Non-EnGCFE when compared to the control group, but not
at 100, 1000 and 2500 mg/kg bw. Although such an
effect did not appear to be dose-dependent, it could
be so in a longer subacute test. A decrease in kidney
weight can happen due to malnutrition or even to
atrophy induced by reduced water consumption,
but both situations must be excluded in the present
study for both male and female groups. Moreover,
gross examination of the main organs including
liver, spleen, stomach, kidneys, lungs, heart, and
brain did not show any abnormal ﬁndings (data not
shown). Therefore, these results taken together

indicate that oral administration of a single dose
until 2500 mg/kg bw did not show toxic effects in
mice. However, there were mild reversible reactions
which may be suggestive of caffeine action on the
central nervous system.
Even among dead mice, neither macroscopic
alteration in selected organs nor relative organ
weight alteration were observed. Despite being
clear the role of caffeine in these fatal intoxications,
speciﬁc organ alterations, i.e. brain edema and mild
erosion with hemorrhage in the stomach caused by
caffeine overdose [41], were not observed in this
toxicity study.
Acute toxicity not only provides initial information on the mode of toxic action of a substance, but
also allows establishing a safe dose of a new compound and is helpful in determining doses in animal
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Fig. 2. Female and male mice water consumption during 14-day after single dose of En-GCFE and Non-En-GCFE. *encapsulated (En-) and
non-encapsulated (Non-En-) green coffee fruit extract (GCFE).

studies [34]. Based on this, doses until 1000 mg/kg
bw of En-GCFE, which were well tolerated in the
acute test, were selected to conduct a subacute study
in male Wistar rats in order to calculate the noobserved-adverse-effect level (NOAEL) and to help
in clinical studies.
3.2. Subacute toxicity
Since the toxicological proﬁle of GCFE may have
been inﬂuenced by a synergistic effect of compounds,
in vivo data are essential to be sure of its safety. For this

purpose, repeated dose toxicity testing is usually carried out for no less than 28 days, with the test substance administered daily preferentially through the
oral route [31], and a rodent of any gender and age of
5e6 weeks selected as a model [47]. In this study, the
subacute test was conducted orally administering to
male rats only En-GCFE via gastrogavage for 30 days,
because this extract was proven to exert less adverse
effect than Non-En-GCFE in Hippocratic screening.
During this period, no treatment-related clinical
symptoms or death were recorded, and autonomic
and central nervous system, somatomotor activity and
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*p  0.05 and **p  0.01 represent signiﬁcant differences from the control group.
a
Relative body weight (%) ¼ [(g/g body weight) x 100].
b
Encapsulated (En-) and.
c
Non-encapsulated (Non-Enc-) green coffee fruit extract (GCFE). Results are expressed as mean ± standard error of mean (SEM) of 6 mice. Analysis by ANOVA followed by
TukeyeKramer test.
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0.04
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100
Control
2500
1000
500
100
Control

Non-En-GCFE
Spleen (%)
Heart (%)
Stomach (%)
Liver (%)
Lungs (%)
Kidneys (%)
c
En-GCFE
Spleen (%)
Heart (%)
Stomach (%)
Liver (%)
Lungs (%)
Kidneys (%)

b

Males (dose, mg/kg bw)
Organ/Groups

Table 3. Relative body weights (%)a of female and male mice after 14-days toxicity study.

5000

Females (dose, mg/kg bw)

500

0.59
0.55
1.11
4.56
0.75
1.14

±
±
±
±
±
±

0.02
0.02
0.07
0.09
0.03
0.03

0.61
0.54
1.05
4.51
0.74
1.16

1000

±
±
±
±
±
±

0.03
0.05
0.04
0.21
0.03
0.06

0.44
0.51
1.02
4.71
0.72
0.99

2500

±
±
±
±
±
±

0.02
0.04
0.12
0.21
0.02
0.24

5000
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0.53
0.66
1.19
4.82
0.91
1.21
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behavior pattern were found to be normal in all the
experimental groups.
3.2.1. Body weight, food intake and water
consumption
There were no signiﬁcant differences in body
weight, water consumption, feces weight, food
intake (Fig. 3), or feeding efﬁciency (data not shown)
in treated animals compared to the control group
(p > 0.05). En-GCFE did not affect gastrointestinal
transit since symptoms like diarrhea or intestinal
constipation were not observed, feces weight
increased at the last time-point in accordance with
animal growth (Fig. 3D), and food intake, body
weight, and water consumption varied only a little
throughout the study (Fig. 3AeC). In addition, the
moderate, but non-signiﬁcant decrease in body
weight gain occurred among animals of the control
group after 7 weeks (data not shown) and in the last
week indicates food avoidance, which may have
happened due to some discomfort caused by gastrogavage. Differently, in their 90-day dietary subchronic study, Heimbach et al. [25] observed
signiﬁcant body weight gain, food consumption and
food efﬁciency at dosages of 3446 and 4087 mg/
kg bw/day, which however were not considered
adverse or toxicologically signiﬁcant.
3.2.2. Relative and absolute organ weights and
histopathological ﬁndings
Systemic toxicity manifests itself through decreases in ponderal development as well as food
and water consumption, behavioral alteration,
apathy, bad condition of the coat such as hair loss,
biochemical and hematological alterations, and
relative organ weight alterations [48e50]. In the
present study, the terminal body weight of rats did
not show any signiﬁcant difference (p > 0.05) when
comparing the groups treated with En-GCFE and
the control group (Table 4 and Fig. 3).
No signiﬁcant difference was even found in relative or absolute rat organ weights (Table 4).
Contrariwise, Heimbach et al. [25] observed some
statistically signiﬁcant changes in these parameters
for kidneys, heart and liver using either mid
(~2000 mg/kg bw/day) or high dose (~4000 mg/
kg bw/day) of ethanolic extract from whole coffee
fruit incorporated in rat diet.
Figs. 4e6 shows photomicrographs of some of
main organs analyzed histologically. The section of
heart, liver and kidney tissues stained with hematoxylin and eosin revealed normal morphology
without inﬂammatory cell inﬁltration. In all groups,
including the control, some alterations were
observed in the superﬁcial stomach tissue, which
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Fig. 3. Subacute toxicity study using male Wistar rats treated with encapsulated green coffee whole fruit extract. (A) body weight gain, (B)
feed intake, (C) water consumption and (D) feces weight.

suggest colonization by Candida sp., whereas no
alteration was evident in other stomach regions.
Some studies reported effects of coffee and its
compounds such as caffeine and chlorogenic acid on
the gastrointestinal system [51-53]. Both coffee and
caffeine can stimulate gastrin hypersecretion and
gastric acid secretion causing mild erosive and
hemorrhagic points in stomach [41,51,52]. Decaffeinated coffee, which is commonly produced from
the same Robusta beans used in this study, was
found to be more acidic than the regular one due to
higher concentrations of organic acids such as
chlorogenic acid compared with the Arabica ones
[54]. Nevertheless, En-GCFE did not cause any
macro or microscopic damage in the architecture of

the stomach mucosa, likely due to protection of
superﬁcial tissue of this organ from CGFE offered
by the Arabic gum (GA)/maltodextrin (MD) wall
material. The role of GA as prebiotic and antioxidant agent has been studied widely [55e57], and its
effectiveness in targeted delivery has been ascribed
to resistance in stomach and small intestine [58].
Moreover, combinations of MD and GA like that
used in this study have been proposed to protect
phenolic compounds [59,60].
At dosage of 1000 mg/kg bw/day, no alteration in
the architecture or inﬂammatory inﬁltration was
observed in the large or small intestine structures
likely because microencapsulation protected intestine endothelium from chlorogenic acids and
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Table 4. Terminal body weight, absolute and relative main organs weightsa from subacute toxicity study using male rats.
Treatment with encapsulated GCFE (mg/kg bw/day)

Terminal body weight (g)
Brain weight (g)
Relative brain weight (%)a
Liver weight (g)
Relative liver weight (%)
Heart weight (g)
Relative heart weight (%)
Lungs weight (g)
Relative lungs weight (%)
Stomach weight (g)
Relative stomach weight (%)
Spleen weight (g)
Relative spleen weight (%)
Kidney weight (g)
Relative kidney weight (%)
Testis weight (g)
Relative testis weight (%)

Control

100

500

1000

296.3 ± 10.2
1.91 ± 0.04
0.65 ± 0.02
12.27 ± 0.60
4.12 ± 0.08
1.21 ± 0.05
0.40 ± 0.01
2.16 ± 0.16
0.72 ± 0.04
1.97 ± 0.07
0.67 ± 0.02
0.81 ± 0.04
0.27 ± 0.01
2.84 ± 0.11
0.96 ± 0.03
3.75 ± 0.17
1.27 ± 0.06

298.2 ± 8.8
1.84 ± 0.05
0.62 ± 0.02
12.96 ± 0.55
4.34 ± 0.13
1.24 ± 0.05
0.41 ± 0.02
2.37 ± 0.12
0.80 ± 0.04
1.88 ± 0.08
0.63 ± 0.03
0.81 ± 0.04
0.27 ± 0.01
2.91 ± 0.10
0.98 ± 0.02
3.37 ± 0.01
1.13 ± 0.03

300.9 ± 12.2
1.86 ± 0.05
0.62 ± 0.03
13.04 ± 0.66
4.33 ± 0.14
1.16 ± 0.05
0.38 ± 0.01
2.14 ± 0.08
0.72 ± 0.03
1.93 ± 0.08
0.65 ± 0.04
0.80 ± 0.04
0.26 ± 0.06
3.01 ± 0.10
1.00 ± 0.02
3.36 ± 0.15
1.13 ± 0.07

296.9 ± 7.8
1.84 ± 0.04
0.62 ± 0.02
12.16 ± 0.70
4.07 ± 0.12
1.18 ± 0.05
0.39 ± 0.01
2.08 ± 0.13
0.70 ± 0.05
1.88 ± 0.12
0.63 ± 0.04
0.80 ± 0.03
0.27 ± 0.01
2.87 ± 1.13
0.96 ± 0.02
3.31 ± 0.15
1.12 ± 0.07

*p  0.05 and **p  0.001 represent signiﬁcant differences from the control group.
a
Relative body weight (%) ¼ [(g/g body weight) x 100]. Results were expressed as mean ± standard error of mean (SEM) of 6 rats.
Analysis by ANOVA followed by TukeyeKramer test.

caffeine present in GCFE. Contrariwise, Du et al.
[61] reported that a high dose of chlorogenic acid
(7 mg/kg bw) administered via parenteral route
caused severe architecture damage, manifested by
loss of ileum villi, villus congestion and massive

inﬁltration of inﬂammatory cells, as the likely result
of oxidative stress due to an increase in reactive
oxygen species and, consequently, to enhancement
of inﬂammatory mediators in intestinal endothelium. A dose as high as 4000 mg/kg bw/day of

Fig. 4. Photomicrographs of heart (50 mm) analyzed histologically. H1 ¼ control group; H2 ¼ 100 mg/kg bw/day; H3 ¼ 500 mg/kg bw/day;
H4 ¼ 1000 mg/kg bw/day.
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Fig. 5. Photomicrographs of liver (50 mm) analyzed histologically. L1 ¼ control group; L2 ¼ 100 mg/kg bw/day; L3 ¼ 500 mg/kg bw/day;
L4 ¼ 1000 mg/kg bw/day.

ethanolic extract from whole coffee fruit, containing
40% phenolic acids and 0.6e9.0% caffeine and
administered orally for 14 days, caused colon/intestinal distention in 3 of 10 female rats, but it was

not considered a toxic effect since no histopathological alteration was seen [25]. A possible reason of
conﬂicting results is the different administration
route employed in these studies.

Fig. 6. Photomicrographs of kidney (50 mm) analyzed histologically. K1 ¼ control group; K2 ¼ 100 mg/kg bw/day; K3 ¼ 500 mg/kg bw/day;
K4 ¼ 1000 mg/kg bw/day.
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In a chronic study conducted by Chan et al. [62],
where 1000 mg/kg bw/day green tea extract were
administered by gavage for 3 months, liver alterations
were found in 3 of 10 female rats likely due to its
content of caffeine (4.99%, ~15 mg/kg bw), which is
known to act as a potent CYP1A2 inducer [63]. However, despite its higher caffeine content (24 mg/kg bw/
day), En-GCFE did not lead, in the present study, to
any macroscopic or histological liver alteration among
treated or control male rats; neither did it cause
structural alteration in testis, corroborating ﬁndings
reported by Heimbach et al. [25].
Despite no organ weight changes, some alterations in brain and lungs were seen in both treated
and control animals. Particularly, midbrain-diencephalic junction and rostrocaudal brain region
showed mild neutrophil vacuolization and mild
acute neuronal necrosis, which, however, were
presumably due to the increased brain glutamate
postmortem levels caused by the CO2 euthanasia
protocol [64]. In addition, CO2 anesthetic levels may
have been responsible for hemorrhage and acidosis
observed in the brain [65]. Moderate alveolar wall
thickening with the presence of mononuclear and
polymorphonuclear cell inﬁltrates and the absence
of any bacterial agent in lung tissue were also
observed among all animal groups, including the
control one, but these ﬁndings are commonly
observed in enclosed individuals [66]. No histological alterations in treated groups were signiﬁcant
compared to the control animals, thereby excluding
any role of En-GCFE in tissue toxic effect.
3.2.3. Biochemical and hematological parameters
Consumption of En-GCFE caused no alteration
in hematological parameters and only small
changes in biochemical parameters of the treated
animals compared to the control ones. Speciﬁcally,
mean albumin concentration was found to
decrease at the highest En-GCFE dose, while
glucose concentration to increase at 500 and
1000 mg/kg bw/day compared to the control group
(p < 0.05). Likewise, Heimbach et al. [25] found
only mild signiﬁcant alterations in mean platelets
concentration when using mid (2030 mg/kg bw/
day) and high (4087 mg/kg bw/day) doses of whole
coffee fruit extract as well as an increased glucose
level at low dose (965 mg/kg bw/day) after a 90-day
dietary study.
Albumin is a well-known body's predominant
serum-binding protein responsible for the transport
of various compounds, including bilirubin, fatty
acids, metals, ions, hormones and exogenous drugs
[67], whose level can be decreased by various

adverse
conditions
including
malnutrition,
nephrotic syndrome, hepatic cirrhosis, heart failure
and, more commonly, acute and chronic inﬂammatory responses [68]. However, although all
groups exhibited a serum albumin level below the
reference range indicated by Giknis and Clifford
[69], no other hematological or biochemical alterations ascribable to possible causes of hypoalbuminemia were found in comparison to the
control group (Table 5), such as increased levels of
blood cells indicating inﬂammatory process, or of
biomarkers of liver and heart function (aspartate
aminotransferase, alanine aminotransferase and
alkaline phosphatase), or even of more speciﬁc
markers of liver (g-glutamyl transpeptidase, total,
direct and indirect bilirubin) and kidney (urea,
creatinine and uric acid) functions. In addition, even
though lab markers of malnutrition such as globulin
and total protein decreased, reducing total cholesterol level and lymphocytes count [70], such variations were not statistically signiﬁcant when
compared to the control group (p > 0.05).
The dose-dependent raise in serum glucose level
in healthy rats disagrees with the in vitro antidiabetic effect of green coffee extract reported by
Henry-Vitrac et al. [71], as well as the capability of
trigonelline and chlorogenic acids taken through
regular coffee consumption to lower the risk of type
2 diabetes mellitus in humans [72e75], and to exert
an anti-hyperglycemic effect in diabetic rats [76].
Finally, En-GCFE ingestion did not lead to any statistically signiﬁcant increase in cortisol level
compared to the control group (p > 0.05), like that
induced by caffeine and coffee on this and other
stress hormones [77,78].
In summary, these results taken as whole
demonstrate that oral administration of En-GCFE
did not cause any deterioration of hematological
and biochemistry parameters, thereby conﬁrming
the ﬁndings of histopathological analyses that
showed a normal tissue architecture in all selected
organs. Besides, no alterations of clinical signs and
behavior were observed among the treated and
control groups even at the highest dose.
These ﬁndings allowed establishing an En-GCFE
NOAEL of 1000 mg/kg bw/day for male rats.
Considering the human equivalent dose deﬁned by
Equation (1), the safe dose established for humans is
189 mg/kg bw/day or 11.34 g/day considering an
adult with 60 kg of body weight. Nonetheless, it is
worth mentioning that the above equation assumes
body surface area as the unique important characteristic, not considering physiological, biochemical
and pharmacokinetic aspects.

Table 5. Effects on haematological and biochemical parameters in male rats after 30-day of ingestion of encapsulated GCFE.
Hematological parameters
Red blood cell (106/mL)
Hemoglobin (g/dL)
Hematocrit (%)
MCV (m3)
MCH (pg)
MCHC (%)
Leukocytes (103/ml3)
Segmented (%)
Eosinophils (%)
Basophils (%)
Lymphocytes (%)
Monocytes (%)
Platelets (103/mL)
Biochemical parameters
Glucose (mg/dL)
Ur (mg/dL)
Cre (mg/dL)
CHO (mg/dL)
HDL (mg/dL)
LDL (mg/dL)
VLDL (mg/dL)
TG (mg/dL)
UA (mg/dL)
TBILI (mg/dL)
DBILI (mg/dL)
IBILI (mg/dL)
TP (g/dL)
Alb (g/dL)
Globulins (g/dL)
ALT (UI/L)
AST (UI/L)
AMI (UI/L)
GGT (UI/L)
ALP (UI/L)
COR (mg/dL)

Treatment with encapsulated GCFE (mg/kg bw/day)
Control

100

500

1000

ReferenceA

8.81 ± 0.21
16.09 ± 0.40
51.44 ± 1.22
58.51 ± 1.27
18.28 ± 0.34
31.28 ± 0.28
6.67 ± 1.58
21.56 ± 6.04
6.33 ± 0.92
0
70.11 ± 6.63
1.33 ± 0.16
748.89 ± 76.12

8.91 ± 0.27
16.31 ± 0.57
51.67 ± 1.89
58.01 ± 1.34
18.33 ± 0.44
31.60 ± 0.35
9.61 ± 0.83
14.44 ± 1.11
7.67 ± 0.78
0
76.33 ± 1.43
1.56 ± 0.17
814.22 ± 60.48

8.76 ± 0.19
15.95 ± 0.21
50.88 ± 0.87
58.21 ± 1.21
18.25 ± 0.37
31.37 ± 0.24
6.77 ± 0.86
16.88 ± 1.34
7.33 ± 0.37
0
70.55 ± 1.27
1.88 ± 0.77
871.22 ± 58.09

8.18 ± 0.30
14.92 ± 0.44
46.62 ± 1.73
57.08 ± 1.11
18.30 ± 0.37
32.07 ± 0.32
7.7 ± 1.01
15.5 ± 1.10
8.00 ± 0.73
0
75.25 ± 1.08
1.25 ± 0.16
792.04 ± 79.04

7.27e9.65
13.7e17.6
39.6e52.5
48.9e57.9
17.1e20.4
32.9e37.5
1.96e8.25
6.2e27.6
0.2e3.5
0
66.6e90.3
0.8e3.8
638e1177

72.32 ± 7.65a
51.54 ± 3.46
0.77 ± 0.04
100.11 ± 4.19
43.98 ± 2.40
46.32 ± 2.68
9.80 ± 0.75
53.10 ± 2.88
1.03 ± 0.08
0.10 ± 0.02
0.03 ± 0.00
0.07 ± 0.01
7.65 ± 0.22
3.11 ± 0.07a
4.53 ± 0.17
57.76 ± 6.43
130.20 ± 26.58
468.48 ± 45.73
6.73 ± 0.85
121.15 ± 10.45
0.81 ± 0.02

77.77 ± 4.60a
53.22 ± 3.49
0.80 ± 0.03
110.65 ± 7.30
46.73 ± 1.79
49.58 ± 7.40
11.96 ± 1.60
66.44 ± 6.93
1.41 ± 0.23
0.09 ± 0.03
0.02 ± 0.00
0.07 ± 0.02
7.60 ± 0.18
3.24 ± 0.07a
4.34 ± 0.12
66.28 ± 3.73
137.84 ± 23.80
480.01 ± 38.46
5.74 ± 0.75
103.18 ± 9.04
0.82 ± 0.02

88.31 ± 9.50b*
45.28 ± 2.11
0.71 ± 0.01
99.55 ± 6.10
43.24 ± 2.33
43.20 ± 6.01
10.56 ± 1.41
65.55 ± 8.43
1.50 ± 0.36
0.10 ± 0.03
0.02 ± 0.00
0.07 ± 0.03
7.25 ± 0.20
2.96 ± 0.07a
4.28 ± 0.15
60.24 ± 6.47
125.36 ± 23.13
493.64 ± 37.57
7.90 ± 0.97
102.91 ± 11.14
0.84 ± 0.02

90.95 ± 12.67b*
43.28 ± 3.04
0.68 ± 0.01
97.01 ± 7.98
40.46 ± 3.05
50.16 ± 7.79
10.80 ± 1.11
54.30 ± 3.92
1.17 ± 0.22
0.13 ± 0.05
0.02 ± 0.00
0.10 ± 0.05
7.07 ± 0.18
2.73 ± 0.11b*
4.33 ± 0.18
58.27 ± 8.01
129.38 ± 26.13
442.18 ± 25.37
7.07 ± 0.58
103.08 ± 6.54
0.84 ± 0.02

70e208
10.7e20.0
0.3e0.5
37e95
e
e
e
27e140
e
0.05e0.15
0.03e0.05
0.01e0.12
5.2e7.1
3.4e4.8
1.58e2.67
18e45
74e143
e
e
62e230
e

Results are expressed as mean ± standard error of mean (SEM) of 10 trials. One-way ANOVA followed by TukeyeKramer test. *p  0.05
and **p  0.01 represent signiﬁcant differences from the control group. Difference (p  0.05) between groups of the same treatment
represented by the letters a, b and c. Glu, glucose; AMI, amylase; Ur, urea; LDL, low density lipoprotein; VLDL, very low-density lipoprotein; HDL, high density lipoprotein; TG, triglycerides; CHO, total cholesterol; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; ALP, alkaline phosphatase; GGT, g-glutamyl transferase; Alb, albumin; TP, total protein; UA, uric acid; Cre, creatinine; TBILI, total bilirubin; DBILI, direct bilirubin; IBILI, indirect bilirubin, FAL, alkaline phosphatase. COR, cortisol.
A
Giknis & Clifford [69].

3.3. Behavioral test
The autonomic effects observed among mice after
an oral single dose of 2500 and 5000 mg/kg bw of
Non-En-GCFE allowed selecting a maximum limit
dose of 2000 mg/kg bw by the open-ﬁeld test.
In the study proposed by Nehlig et al. [79],
caffeine supplied in gavage exerted muscle relaxant
activities and sedative effects or psychostimulant
effects. These possible nonspeciﬁc effects of NonEn-GCFE neither changed the number of rearings
and crossings when compared to the control group
after 60 min of administration until doses of 1000

and 2000 mg/kg bw, respectively (Fig. 7). On the
other hand, statistically signiﬁcant increase in the
number of crossings (p < 0.01) and decrease in that
of rearings (p < 0.01) were observed after 30 min
among animals that received a dose of 1000 mg/kg
bw compared to the control ones. The group treated
with 2000 mg/kg bw decreased signiﬁcantly the
number of rearings after 30 and 60 min of administration of Non-En-GCFE (Fig. 7).
It was reported by Czok and Lang [80] that
chlorogenic acid alone had a weak neurostimulating
effect in rats, but chlorogenic acid co-administered
with caffeine showed an enhanced, dose-dependent
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30 min after receiving a dose of 1000 mg/kg bw, but
not by the number of rearings. On the other hand, at
a dose of 2000 mg/kg bw a signiﬁcant neurodepressive effect referred to the number of crossings took place compared to other treated groups
(p < 0.05) (data not shown), but not compared to the
control (p > 0.05). These results may be ascribed to
some discomfort caused by the extract like that
observed at 2500 mg/kg dosage in the Hippocratic
screening, given that high doses of caffeine can
cause hypotension, dizziness, nausea, among other
symptoms [41].

4. Conclusion

Fig. 7. Number of crossings and rearings after 30 and 60 min of the
GCFE single dose. Results are expressed as mean ± standard error
(SEM) of 6 samples. One-way ANOVA followed by TukeyeKramer test.
*p  0.05 and **p  0.01 represent signiﬁcant differences from the
control group.

central stimulant action. In a more recent study
assessing the effects of chlorogenic, caffeic and mcoumaric acids on spontaneous locomotor activity in
mice, Ohnishi et al. [81] observed that chlorogenic
acid has a weak caffeine-like psychostimulant effect,
but at a dose of 2.8 mmol/kg it signiﬁcantly
increased locomotor activity, although more weakly
than the other two acids. In a clinical random trail,
adult males who received 200 mg of caffeine from
green coffee extract showed an increase in
epinephrine level similar to the control, but no signiﬁcant change in blood pressure or heart rate from
baseline levels after 60 and 120 min post-GCFE
dose, thereby suggesting that natural caffeine
sources may have different impacts on excitatory
neurotransmitters, particularly epinephrine [78].
In the present study, the stimulant effect of GCFE
was shown by the increased number of crossings

Acute toxicity tests provided important information on the safety of encapsulated (En-) and nonencapsulated (Non-En-) green coffee fruit extract
(GCFE) and allowed determining for the former a
median lethal dose (LD50) in mice of 5000 mg/
kg bw/day. Despite En-GCFE contained theoretically the same amount of 5-CQA taken as a chemical
marker as Non-En-GCFE, it was not possible to
determine its LD50 likely due to a delay in the
release of the caffeine. Doses of 100, 500 and
1000 mg/kg bw/day of En-GCFE, prepared to
furnish the same amounts of chemicals as in NonEn-GCFE, were selected to assess the subacute
safety in male Wistar rats, since they showed fewer
side effects in the Hippocratic screening. In the
subacute toxicity assay, oral administration of the
highest dose (1000 mg/kg bw/day) of En-GCFE for
30 days did not lead to any adverse effects; therefore, it was assumed as no-observed-adverse-effect
level, which allowed estimating a human equivalent
dose for an adult with 60 kg of body weight of
189 mg/kg bw/day or 11.34 g/day. These results
indicate that En-GCFE could be safe for daily
consumption.
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